[1] Sciuto R, Romano L, Rea S, et al.  Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution[J]. Ann Oncol, 2009, 20(10): 1728-1735.   doi: 10.1093/annonc/mdp050
[2] Muresan MM, Olivier P, Leclère J, et al.  Bone metastases from differentiated thyroid carcinoma[J]. Endocr Relat Cancer, 2008, 15(1): 37-49.   doi: 10.1677/ERC-07-0229
[3] Mihailovic JM, Stefanovic LJ, Malesevic MD, et al.  Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases[J]. Nucl Med Commun, 2009, 30(7): 558-564.   doi: 10.1097/MNM.0b013e32832cc2ab
[4] Durante C, Haddy N, Baudin E, et al.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy[J]. J Clin Endocrinol Metab, 2006, 91(8): 2892-2899.   doi: 10.1210/jc.2005-2838
[5] Schlumberger M, Tubiana M, De Vathaire F, et al.  Long-term results of treatment of 283 patients with lung ang bone metastases from differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 1986, 63(4): 960-967.   doi: 10.1210/jcem-63-4-960
[6] Sugitani I, Fujimoto Y, Yamamoto N, et al.  Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control[J]. Surgery, 2008, 143(1): 35-42.   doi: 10.1016/j.surg.2007.06.011
[7] Baitei EY, Zou M, Al-Mohanna F, et al.  Aberrant BRAF splicingas an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma[J]. J Pathol, 2009, 217(5): 707-715.   doi: 10.1002/path.2496
[8] Kogai T, Sajid-Crockett S, Newmarch LS, et al.  Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells[J]. J Endocrinol, 2008, 199(2): 243-252.   doi: 10.1677/JOE-08-0333
[9] Ahn SH, Henderson Y, Kang Y, et al.  An orthotopic model of papillary thyroid carcinoma in athymic nude mice[J]. Arch Otolaryngol Head Neck Surg, 2008, 134(2): 190-197.   doi: 10.1001/archoto.2007.36
[10] Younes MN, Kim S, Yigitbasi OG, et al.  Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer[J]. Mol Cancer Ther, 2005, 4(8): 1146-1156.   doi: 10.1158/1535-7163.MCT-05-0078
[11] Schweppe RE, Kerege AA, Sharma V, et al.  Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells tomitogen-activatedproteinkinase kinase 1/2 inhibition[J]. Thyroid, 2009, 19(8): 825-835.   doi: 10.1089/thy.2008.0362
[12] Cheng SP, Yin PH, Chang YC, et al.  Differential roles of leptin in regulating cell migration in thyroid cancer cells[J]. Oncol Rep, 2010, 23(6): 1721-1727.
[13] Schweppe RE, Klopper JP, Korch C, et al.  Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contaminationresultingincelllineredundancyand misidentification[J]. J Clin Endocrinol Metab, 2008, 93(11): 4331-4341.   doi: 10.1210/jc.2008-1102
[14] Klopper JP, Berenz A, Hays WR, et al.  In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma[J]. Clin Cancer Res, 2008, 14(2): 589-596.   doi: 10.1158/1078-0432.CCR-07-0269
[15] Kim S, Yazici YD, Calzada G, et al.  Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice[J]. Mol Cancer Ther, 2007, 6(6): 1785-1792.   doi: 10.1158/1535-7163.MCT-06-0595
[16] Nahari D, Satchi-Fainaro RS, Chen M, et al.  Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer[J]. Mol Cancer Ther, 2007, 6(4): 1329-1337.   doi: 10.1158/1535-7163.MCT-06-0554
[17] Lin X, Zhu B, Liu Y, et al.  Follicular thyroid carcinoma invades venous rather than lymphatic vessels[J]. Diagn Pathol, 2010, 5: 8-.   doi: 10.1186/1746-1596-5-8
[18] Hombach-KlonischS, BialekJ, RadestockY, etal.  INSL3hastumorpromoting activity in thyroid cancer[J]. Int J Cancer, 2010, 127(3): 521-531.   doi: 10.1002/ijc.25068
[19] Ercolino T, Lombardi A, Becherini L, et al.  The Y606C RET mutation causes a receptor gain of function[J]. Clin Endocrinol(Oxf), 2008, 69(2): 253-258.   doi: 10.1111/j.1365-2265.2008.03197.x
[20] Quidville V, Segond N, Tebbi A, et al.  Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice[J]. Thyroid, 2009, 19(6): 613-621.   doi: 10.1089/thy.2008.0194
[21] Vitagliano D, De Falco V, Tamburrino A, et al.  The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells[J]. Endocr Relat Cancer, 2010, 18(1): 1-11.   doi: 10.1677/ERC-09-0292
[22] Chen MC, Yu CH, Wang SW, et al.  Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO[J]. J Cell Biochem, 2010, 110(6): 1495-1503.   doi: 10.1002/jcb.22716
[23] Arcinas A, Yen TY, Kebebew E, et al.  Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns[J]. J Proteome Res, 2009, 8(8): 3958-3968.   doi: 10.1021/pr900278c
[24] Hoffmann S, Rockenstein A, Ramaswamy A, et al.  Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells[J]. Mol Cell Endocrinol, 2007, 264(1-2): 74-81.   doi: 10.1016/j.mce.2006.10.009
[25] Fortin MA, Salnikov AV, Nestor M, et al.  Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies[J]. Eur J Nucl Med Mol Imaging, 2007, 34(9): 1376-1387.   doi: 10.1007/s00259-006-0346-5
[26] Leux C, Guénel P.  Risk factors of thyroid tumors: role of environmental and occupational exposures to chemical pollutants[J]. Rev Epidemiol Sante Publique, 2010, 58(5): 359-367.   doi: 10.1016/j.respe.2010.05.005
[27] Alfano RW, Leppla SH, Liu S, et al.  Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma[J]. Mol Cancer Ther, 2010, 9(1): 190-201.   doi: 10.1158/1535-7163.MCT-09-0694
[28] Hombach-KlonischS, BialekJ, RadestockY, etal.  INSL3hastumorpromoting activity in thyroid cancer[J]. Int J Cancer, 2010, 127(3): 521-531.   doi: 10.1002/ijc.25068
[29] Zatelli MC, Tagliati F, Amodio V, et al.  Role of pituitary tumour transforming gene 1 in medullary thyroid carcinoma[J]. Anal Cell Pathol(Amst), 2010, 33(5): 207-216.
[30] Henderson YC, Ahn SH, Kang Y, et al.  Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement[J]. Clin Cancer Res, 2008, 14(15): 4908-4914.
[31] Nucera C, Nehs MA, Mekel M, et al.  A novel orthotopic mouse model of human anaplastic thyroid carcinoma[J]. Thyroid, 2009, 19(10): 1077-1084.   doi: 10.1089/thy.2009.0055
[32] Kim S, Park YW, Schiff BA, et al.  An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice[J]. Clin Cancer Res, 2005, 11(5): 1713-1721.   doi: 10.1158/1078-0432.CCR-04-1908
[33] Sehiff BA, MeMurphy AB, Jasser SA, et al.  Epidermal growth factor receptor(EGFR)is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer[J]. Clin Cancer Res, 2004, 10(24): 8594-8602.   doi: 10.1158/1078-0432.CCR-04-0690
[34] Zou M, Famulski KS, Parhar RS, et al.  Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100 A4(Mts1)gene overexpression as a poor prognostic marker for thyroid carcinoma[J]. J Clin Endocrinol Metab, 2004, 89(12): 6146-6154.   doi: 10.1210/jc.2004-0418